Cite
HARVARD Citation
Sharman, J. et al. (2019). Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. Leukemia & lymphoma. 60 (4), pp. 894-903. [Online].